Michael P. Meers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael P. Meers has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Steven Henikoff
Basic Sciences Division, Fred Hutchinson Cancer Center, Seattle, USA
40 shared publications - Derek Henry Janssens
Department of Epigenetics, Van Andel Institute, Grand Rapids, MI, USA
38 shared publications - Jay F. Sarthy
Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children’s Research Institute
37 shared publications - Kami Ahmad
Basic Sciences Division, Fred Hutchinson Cancer Center, Seattle, USA
35 shared publications - Sandipan Brahma
Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE 68198, United States
35 shared publications - Anna-Lisa Doebley
Division of Public Health Sciences Fred Hutchinson Cancer Center 1100 Fairview Ave. N 98109 Seattle WA
34 shared publications
Latest Publications
- 4 June 2026
- Published by Springer Nature in Nature Reviews Methods Primers
- Vol. 6 (1)
Enzyme tethering for in situ epigenomics
- 4 June 2026
- Published by Springer Nature in Nature Reviews Methods Primers
- Vol. 6 (1)
Enzyme tethering for in situ epigenomics
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
Supplementary Figures S1-S18 and Supplementary Table legends.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
Supplementary Figures S1-S18 and Supplementary Table legends.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
PDX sequencing metrics Phenotype and sequencing metrics for all PDX LuCaP lines.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
PDX sequencing metrics Phenotype and sequencing metrics for all PDX LuCaP lines.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
PTM peak data and phenotype 47 fragment variability Sheet 1: PDX sample representation in 3 histone PTM CUT&RUN nucleosome profiling assays (H3K4me1, H2K27ac and H3K27me3). Sheet 2: Log2 fold-change, p-value, and q-value between ARPC and NEPC lines for coefficient of variation in the 47 phenotype defining gene bodies (two tailed Mann-Whitney U test, Benjamini-Hochberg adjusted). Sheet 3: Log2 fold-change, p-value, and q-value between ARPC and NEPC lines for coefficient of variation in the 47 phenotype defining gene promoters (two tailed Mann-Whitney U test, Benjamini-Hochberg adjusted).
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
PTM peak data and phenotype 47 fragment variability Sheet 1: PDX sample representation in 3 histone PTM CUT&RUN nucleosome profiling assays (H3K4me1, H2K27ac and H3K27me3). Sheet 2: Log2 fold-change, p-value, and q-value between ARPC and NEPC lines for coefficient of variation in the 47 phenotype defining gene bodies (two tailed Mann-Whitney U test, Benjamini-Hochberg adjusted). Sheet 3: Log2 fold-change, p-value, and q-value between ARPC and NEPC lines for coefficient of variation in the 47 phenotype defining gene promoters (two tailed Mann-Whitney U test, Benjamini-Hochberg adjusted).
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
Feature-region combination AUCs and benchmarking Sheet 1: Log2 fold-change, p-value, and q-value between ARPC and NEPC lines for central mean coverage in all queried (338) TFs (two tailed Mann-Whitney U test, Benjamini-Hochberg adjusted). Sheet 2: 100-fold cross-validation AUCs for all region and feature combinations subset by the ‘AR10’ overlapping features (see Methods). Sheet 3: 100-fold cross-validation AUCs for all region and feature combinations subset by the ‘Phenotype 47-defining’ overlapping features. Sheet 4: 100-fold cross-validation AUCs for all region and feature combinations (global). Sheet 5: Predictions scores, tumor fraction, depth of coverage, and subtype for benchmarking admixtures. Sheet 6: AUCs for unsupervised prediction of admixture subtypes grouped by tumor fraction and depth. Sheet 7: NEPC:ARPC ratio, tumor fraction, and ARPC and NEPC fraction predictions for mixed phenotype admixtures using Keraon (see Methods).
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
Feature-region combination AUCs and benchmarking Sheet 1: Log2 fold-change, p-value, and q-value between ARPC and NEPC lines for central mean coverage in all queried (338) TFs (two tailed Mann-Whitney U test, Benjamini-Hochberg adjusted). Sheet 2: 100-fold cross-validation AUCs for all region and feature combinations subset by the ‘AR10’ overlapping features (see Methods). Sheet 3: 100-fold cross-validation AUCs for all region and feature combinations subset by the ‘Phenotype 47-defining’ overlapping features. Sheet 4: 100-fold cross-validation AUCs for all region and feature combinations (global). Sheet 5: Predictions scores, tumor fraction, depth of coverage, and subtype for benchmarking admixtures. Sheet 6: AUCs for unsupervised prediction of admixture subtypes grouped by tumor fraction and depth. Sheet 7: NEPC:ARPC ratio, tumor fraction, and ARPC and NEPC fraction predictions for mixed phenotype admixtures using Keraon (see Methods).
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
Differential regulation metrics and values for select features Sheet 1: Log2 fold-change, p-value, and q-value between ARPC and NEPC lines for NPS in the 47 phenotype defining gene bodies (two tailed Mann-Whitney U test, Benjamini-Hochberg adjusted). Sheet 2: Differentially expressed list of 514 transcription factor (TF). All statistical comparison and fold change estimation was done against ARPCs. Sheet 3: Log2 fold-change, p-value, and q-value between ARPC and NEPC lines for central mean coverage in 108 TFs overlapping RNA-Seq up/down regulated TFs (two tailed Mann-Whitney U test, Benjamini-Hochberg adjusted). Sheet 4: Paralogous transcription factors (TFs) for each of the 38 TFs with differential RNA expression between ARPC and NEPC and differential TFBS accessibility. Paralogous TFs that are also differentially expressed by RNAseq analysis of PDX tumors are shown in red text. Paralogs were obtained from ensembl biomart human genes GRCh38.p13 (http://uswest.ensembl.org/biomart/martview/64d8bd7fe9851a2501aece9b74b03631) Sheet 5: Mean values in ARPC, NEPC, and HD lines for central and window means for ARPC and NEPC specific open chromatin regions.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
Differential regulation metrics and values for select features Sheet 1: Log2 fold-change, p-value, and q-value between ARPC and NEPC lines for NPS in the 47 phenotype defining gene bodies (two tailed Mann-Whitney U test, Benjamini-Hochberg adjusted). Sheet 2: Differentially expressed list of 514 transcription factor (TF). All statistical comparison and fold change estimation was done against ARPCs. Sheet 3: Log2 fold-change, p-value, and q-value between ARPC and NEPC lines for central mean coverage in 108 TFs overlapping RNA-Seq up/down regulated TFs (two tailed Mann-Whitney U test, Benjamini-Hochberg adjusted). Sheet 4: Paralogous transcription factors (TFs) for each of the 38 TFs with differential RNA expression between ARPC and NEPC and differential TFBS accessibility. Paralogous TFs that are also differentially expressed by RNAseq analysis of PDX tumors are shown in red text. Paralogs were obtained from ensembl biomart human genes GRCh38.p13 (http://uswest.ensembl.org/biomart/martview/64d8bd7fe9851a2501aece9b74b03631) Sheet 5: Mean values in ARPC, NEPC, and HD lines for central and window means for ARPC and NEPC specific open chromatin regions.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
Unsupervised model predictions and patient/validation cohort sequencing metrics Sheet 1: DFCI Cohort I: Tumor phenotype by histology and estimates of tumor fraction, subtyping score, and inferred subtype calls using ctdPheno. Sheet 2: DFCI cohort I: Tumor phenotype by histology and estimates of tumor fraction, subtyping score, and inferred phenotypic subtype calls using different ATAC-seq site restricted analysis using ctdPheno. Sheet 3: DFCI cohort I: Tumor phenotype by histology and estimates of tumor fraction, subtyping score, and inferred phenotypic subtype calls using different ATAC-seq site restricted analysis using Keraon. Sheet 4: DFCI Cohort II: Tumor phenotype by histology, summary of clinical correlatives and estimates of tumor fraction, subtyping score, and inferred subtype calls using ctdPheno. Sheet 5: Histology, tumor fraction, subtype score, NEPC fraction, and subtype calls for WGS and ULP patient samples (UW cohort). Sheet 6: Complete sequencing metrics for DFCI cohort I. Sheet 7: Complete sequencing metrics for DFCI cohort II (ULP). Sheet 8: Complete sequencing metrics for DFCI cohort II (deep WGS) Sheet 9: Complete sequencing metrics and ichorCNA estimated tumor fractions for the UW cohort (ULP). Sheet 10: Complete sequencing metrics for the UW cohort (deep WGS) Sheet 11: Complete sequencing metrics for the healthy donor cohort. Sheet 12: Clinical data summary for UW cohort.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
Unsupervised model predictions and patient/validation cohort sequencing metrics Sheet 1: DFCI Cohort I: Tumor phenotype by histology and estimates of tumor fraction, subtyping score, and inferred subtype calls using ctdPheno. Sheet 2: DFCI cohort I: Tumor phenotype by histology and estimates of tumor fraction, subtyping score, and inferred phenotypic subtype calls using different ATAC-seq site restricted analysis using ctdPheno. Sheet 3: DFCI cohort I: Tumor phenotype by histology and estimates of tumor fraction, subtyping score, and inferred phenotypic subtype calls using different ATAC-seq site restricted analysis using Keraon. Sheet 4: DFCI Cohort II: Tumor phenotype by histology, summary of clinical correlatives and estimates of tumor fraction, subtyping score, and inferred subtype calls using ctdPheno. Sheet 5: Histology, tumor fraction, subtype score, NEPC fraction, and subtype calls for WGS and ULP patient samples (UW cohort). Sheet 6: Complete sequencing metrics for DFCI cohort I. Sheet 7: Complete sequencing metrics for DFCI cohort II (ULP). Sheet 8: Complete sequencing metrics for DFCI cohort II (deep WGS) Sheet 9: Complete sequencing metrics and ichorCNA estimated tumor fractions for the UW cohort (ULP). Sheet 10: Complete sequencing metrics for the UW cohort (deep WGS) Sheet 11: Complete sequencing metrics for the healthy donor cohort. Sheet 12: Clinical data summary for UW cohort.
- Open Access
- 24 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (43) , eadv9451
Transgenerational adaptation to hypoxia
Epigenetic inheritance alerts naïve descendants to prepare for stresses that could still be present, whereas distant descendants return to a basal state after several generations without stress. However, organisms are frequently exposed to stresses successively across generations. We found that parental hypoxia exposure increased P0 longevity, caused intergenerational lipid reduction, and elicited transgenerational fertility reduction that was dependent on generationally transmitted small RNAs. Here, we find that Caenorhabditis elegans adapt to repeated generational stresses. We show that, upon two repeated generational hypoxia exposures, the life-span extension is eliminated, and after four repeated generational hypoxia exposures, the reduced fertility is eliminated. Transgenerational adaptation also occurred in response to changes in glucose availability. Transgenerational hypoxia adaptation is dependent on the H3K27 trimethyltransferase PRC2 complex, and we identified transgenerationally adapted genes. Our findings reveal that transgenerational adaptation occurs and suggest that H3K27me3 is a critical modification for adapting to repeated generational stresses.
- 24 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (43) , eadv9451
Open AccessTransgenerational adaptation to hypoxia
Epigenetic inheritance alerts naïve descendants to prepare for stresses that could still be present, whereas distant descendants return to a basal state after several generations without stress. However, organisms are frequently exposed to stresses successively across generations. We found that parental hypoxia exposure increased P0 longevity, caused intergenerational lipid reduction, and elicited transgenerational fertility reduction that was dependent on generationally transmitted small RNAs. Here, we find that Caenorhabditis elegans adapt to repeated generational stresses. We show that, upon two repeated generational hypoxia exposures, the life-span extension is eliminated, and after four repeated generational hypoxia exposures, the reduced fertility is eliminated. Transgenerational adaptation also occurred in response to changes in glucose availability. Transgenerational hypoxia adaptation is dependent on the H3K27 trimethyltransferase PRC2 complex, and we identified transgenerationally adapted genes. Our findings reveal that transgenerational adaptation occurs and suggest that H3K27me3 is a critical modification for adapting to repeated generational stresses.
- Open Access
A protocol for high-throughput microplate-based CUT&Tag
Cleavage Under Targets & Tagmentation (CUT&Tag) is a versatile method for measuring genomic occupancy of chromatin-associated proteins with high sensitivity and specificity. CUT&Tag has low sequencing requirements and is therefore suitable for highly multiplexed experiments, but methods to process samples at throughput without specialized equipment are lacking. Here we present a method for simultaneous parallel processing of 96 CUT&Tag samples in a standard microplate. Plate-CUT&Tag can be carried out in a similar time frame to benchtop CUT&Tag and yields data of comparable quality. We present data from cell culture and patient leukemia samples processed with Plate-CUT&Tag to illustrate its utility in large-scale preclinical and translational studies.
Open AccessA protocol for high-throughput microplate-based CUT&Tag
Cleavage Under Targets & Tagmentation (CUT&Tag) is a versatile method for measuring genomic occupancy of chromatin-associated proteins with high sensitivity and specificity. CUT&Tag has low sequencing requirements and is therefore suitable for highly multiplexed experiments, but methods to process samples at throughput without specialized equipment are lacking. Here we present a method for simultaneous parallel processing of 96 CUT&Tag samples in a standard microplate. Plate-CUT&Tag can be carried out in a similar time frame to benchtop CUT&Tag and yields data of comparable quality. We present data from cell culture and patient leukemia samples processed with Plate-CUT&Tag to illustrate its utility in large-scale preclinical and translational studies.
- Open Access
Intermediately Methylated Regions in Normal Cells Are Epimutation Hotspots in Cancer
DNA methylation is altered in all cancers, but the mechanisms responsible for these changes are not well understood. Using data from 100 primary samples, we show that regions with intermediate methylation in normal hematopoietic cells are hotspots for stable, clonal epimutations in acute myeloid leukemia. Analysis of hematopoietic stem cell clones demonstrated that intermediate methylation at epimutation hotspots reflects random allele-specific methylation and expression at the single cell level, representing a previously unrecognized form of somatically acquired imprinting. We identified somatically imprinted regions in other tissues and show they are epimutation hotspots in other cancer types. This demonstrates that random allele-specific methylation is both a general property of normal cells, and a vulnerability that renders them susceptible to cooperating events and clonal selection during cancer.
Open AccessIntermediately Methylated Regions in Normal Cells Are Epimutation Hotspots in Cancer
DNA methylation is altered in all cancers, but the mechanisms responsible for these changes are not well understood. Using data from 100 primary samples, we show that regions with intermediate methylation in normal hematopoietic cells are hotspots for stable, clonal epimutations in acute myeloid leukemia. Analysis of hematopoietic stem cell clones demonstrated that intermediate methylation at epimutation hotspots reflects random allele-specific methylation and expression at the single cell level, representing a previously unrecognized form of somatically acquired imprinting. We identified somatically imprinted regions in other tissues and show they are epimutation hotspots in other cancer types. This demonstrates that random allele-specific methylation is both a general property of normal cells, and a vulnerability that renders them susceptible to cooperating events and clonal selection during cancer.